How does SRGA.Q's PS Ratio compare to its peers?

SRGA.Q is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (3.8x).

How does SRGA.Q's PS Ratio compare vs other companies in the US Medical Equipment Industry?

SRGA.Q is good value based on its Price-To-Sales Ratio (0x) compared to the US Medical Equipment industry average (3.2x).

What is SRGA.Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate SRGA.Q's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of SRGA.Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate SRGA.Q's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Surgalign Holdings (OTCPK:SRGA.Q) - Stock Price, News & Analysis

SRGA.Q Stock Overview

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. More details

SRGA.Q fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Earnings have declined by 9.6% per year over past 5 years

Does not have a meaningful market cap ($165K)

Negative shareholders equity

Highly volatile share price over the past 3 months

+ 2 more risks

Surgalign Holdings, Inc. Competitors

Procyon

OTCPK:PCYN

US$1.6m

InVitro International

OTCPK:IVRO

US$1.8m

Vycor Medical

OTCPK:VYCO

US$2.9m

Arch Therapeutics

OTCPK:ARTH

US$888.9k

Price History & Performance

Summary of all time highs, changes and price drops for Surgalign Holdings
Historical stock prices
Current Share Price	US$0.018
52 Week High	US$4.00
52 Week Low	US$0.005
Beta	1.49
11 Month Change	63.64%
3 Month Change	-80.00%
1 Year Change	-99.50%
33 Year Change	-99.97%
5 Year Change	-99.99%
Change since IPO	-100.00%

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

Shareholder Returns

	SRGA.Q	US Medical Equipment	US Market
7D	16.1%	1.2%	2.0%
1Y	-99.5%	22.6%	32.4%

Return vs Industry: SRGA.Q underperformed the US Medical Equipment industry which returned -1.8% over the past year.

Return vs Market: SRGA.Q underperformed the US Market which returned 15.2% over the past year.

Price Volatility

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SRGA.Q's share price has been volatile over the past 3 months.

Volatility Over Time: SRGA.Q's weekly volatility has increased from 28% to 40% over the past year.

About the Company

Founded	Employees	CEO	Website
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. It offers products for thoracolumbar procedures, including Streamline TL spinal fixation system, a system for degenerative and complex spine procedures; and Streamline MIS spinal fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability.

Surgalign Holdings, Inc. Fundamentals Summary

How do Surgalign Holdings's earnings and revenue compare to its market cap?
SRGA.Q fundamental statistics
Market cap	US$165.30k
Earnings (TTM)	-US$50.49m
Revenue (TTM)	US$78.12m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is SRGA.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SRGA.Q income statement (TTM)
Revenue	US$78.12m
Cost of Revenue	US$26.03m
Gross Profit	US$52.09m
Other Expenses	US$102.58m
Earnings	-US$50.49m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-5.50
Gross Margin	66.68%
Net Profit Margin	-64.63%
Debt/Equity Ratio	-54.1%

How did SRGA.Q perform over the long term?

See historical performance and comparison

SRGA.Q Stock Overview

Risk Analysis

Surgalign Holdings, Inc. Competitors

OTCPK:PCYN

US$1.6m

OTCPK:IVRO

US$1.8m

OTCPK:VYCO

US$2.9m

OTCPK:ARTH

US$888.9k

Price History & Performance

Recent News & Updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)

Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System